HYPRHyperfine, Inc.
The schedule
- Thu15Oct
Management faces a critical window to execute an equity raise or strategic funding agreement starting near $1.25 to extend the cash runway into 2028.
- Sun15Nov
The final ruling from CMS regarding the 2027 Physician Fee Schedule and hospital outpatient reimbursement rates for portable MRI technology, evaluated from a $1.25 base.
- Tue15Dec
A major operational catalyst anchored at $1.75 surrounding the rollout of next-generation AI-powered image reconstruction software for the Swoop platform.
- Thu11Feb
Q3 results from a $0.95 assumed base provide clarity on final-quarter placement momentum for the Swoop platform and a definitive update on end-of-year capital efficiency.
- Sun28Feb
Full-year 2026 financial disclosure paired with the critical initial 2027 revenue and system placement guidance, tested from a $2.15 base.
- Tue11May
- Fri14May
Past
- Wed12Aug
Actual outcome: Bear
Hyperfine reported Q2 2026 revenue of $3.9 million, up 45% year-over-year, and met EPS estimates at -$0.09. Despite this top-line growth and a subsequent FDA clearance for its Next Optive AI software, the stock plummeted well below the $1.25 bear floor. The severe sell-off indicates that the market remained concerned about the company's operating cash flow and the overall pace of Swoop commercial adoption relative to expectations.
Hyperfine reports Q2 results with critical focus on Swoop commercial adoption, operating cash flow improvements, and updated fiscal H2 2026 guidance, anchored from the $1.60 spot price.
- Tue12May
Actual outcome: Bear · $1.56 at outcome
Stock fell 9.8% from event to outcome date, aligning with the bear trajectory.
First-quarter print evaluating commercial adoption of the Swoop portable MRI system and updates on quarterly cash burn.